Publications

Our team has unmatched expertise in fibrosis biology, and is focused on discovering and developing novel targeted therapies to slow or halt the progression of life-threatening fibrotic diseases. We regularly publish and present our research in a variety of forums.

publications_header_alt

Papers

Dual antagonists of α5β1/αvβ1 integrin for airway hyperresponsiveness
Insights Into Protein-Ligand Interactions in Integrin Complexes: Advances in Structure Determinations
The integrin alpha v beta 6 binds and activates latent TGF beta 1: a mechanism for regulating pulmonary inflammation and fibrosis.
The αvβ1 integrin plays a critical in vivo role in tissue fibrosis.
Targeting of αv integrin identifies a core molecular pathway that regulates fibrosis in several organs.
Epithelial-mesenchymal interactions in fibrosis and repair. Transforming growth factor-β activation by epithelial cells and fibroblasts.
Evaluation of integrin αvβ6 cystine knot PET tracers to detect cancer and idiopathic pulmonary fibrosis.
Integrin alphavbeta6 is a marker of the progression of biliary and portal liver fibrosis and a novel target for antifibrotic therapies.

Posters

Asset 1

Pliant Therapeutics, Inc.
260 Littlefield Avenue,
South San Francisco, CA 94080
info@pliantrx.com
650.481.6770

Our Science

Product Discovery Engine
Publications

Leadership Team
Scientific Founders
Board of Directors
Scientific Advisory Board

Registries
Clinical Trial Access
Community

Investors & Media

Copyright © [year] Pliant Therapeutics, Inc. | All Rights Reserved | Terms of Use | Privacy Notice | CCPA Applicant and Staff Privacy Notice | Forward-Looking Statements